<DOC>
	<DOCNO>NCT00624143</DOCNO>
	<brief_summary>Hypothesis : Oral Voriconazole effective intravenous Amphotericin B antifungal prophylaxis induction acute leukemia ( ALL , AML ) pediatric patient , less toxicity convenience .</brief_summary>
	<brief_title>Antifungal Prophylaxis Pediatric Acute Leukemia</brief_title>
	<detailed_description>RATIONALE OF STUDY : - In induction chemotherapy childhood acute leukemia , experience international study show 30 % ALL approximately 50 % AML patient require antifungal therapy . Mortality rate associate documented fungal infection due opportunistic yeast filamentous fungi high , range 50-90 % despite use therapeutic amphotericin B voriconazole . - Currently license drug use pediatric patient amphotericin B lipid derivative ; 5-flucytosine ; azoles like fluconazole , itraconazole , voriconazole ; caspofungin . - Limitation Fluconazole- inactive Aspergilosis , C. glabrata , C. krusei , C. parapsilosis filamentous fungi . - Limitation Itraconazole- erratic oral absorption capsule form , frequent drug interaction , non availability oral suspension form use small child would able take capsule . - Amphotericin B Voriconazole proven activity filamentous fungi candida specie . - There prospective , randomised trial compare voriconazole amphotericin B prophylaxis pediatric acute leukemia induction . Hence need study role prophylaxis infection high mortality despite therapy . Study design : Prospective , Randomized , conceal , single institutional study . Study population : Pediatric patient acute leukaemia undergo induction chemotherapy IRCH Jan 2008 Dec 2009 eligible study . Inclusion criterion : - Patients age less equal 15 year de novo acute leukemia undergo induction chemotherapy . - No evidence fungal infection randomization - No pneumonia presentation . - No systemic antifungal therapy within 7 day randomization . Febrile patient pneumonia , systemic fungal infection hemodynamically stable eligible study . Exclusion criterion : - Patients baseline pneumonia . - Laboratory evidence significant hepatic renal dysfunction ( define SGOT SGPT 5 time , Total bilirubin 2 time Serum creatinine 2 time upper limit normal ) End point : - Proven probable invasive fungal infection . - Initiation full dose parental antifungal therapy proven probable invasive fungal infection . - Successful recovery ANC 1000/cumm completion induction . Study protocol : - After sign informed consent form patient randomly assign regimen oral Voriconazole IV low dose Amphotericin B . - Oral Voriconazole give dose 6mg/kg 12 hourly day1 4mg/kg 12 hourly daily IV Amphotericin B 0.5 mg/kg/day weekly thrice . - Patient start time initiation induction till completion induction . Evaluation : - Patients evaluated baseline , twice weekly duration study completion study . Baseline evaluation : - History physical examination . - Hemogram biochemistry - Chest X ray Evaluation patient baseline fever : For patient presenting fever baseline ( randomization ) , blood urine culture fungus bacteria send , X- ray chest rule consolidation baseline do patient . The patient start antibiotic per routine institutional policy . If patient becomes afebrile day 5 , antibiotic continue 5 day become afebrile . If patient still febrile day 5 , empiric therapeutic antifungal therapy add . Evaluation patient breakthrough fever : In case patient develop fever &gt; 38 degree C ( axillary ) induction chemotherapy , patient evaluate clinical examination , hemogram , biochemistry , chest X ray , blood urine culture fungus bacterial three consecutive day . Patients evidence chest infection chest X ray/signs symptom chest infection/febrile even receive 5 day appropriate antibiotic subject HRCT scan chest . Patients show consolidation , sign chest infection chest CT subject broncoscopy bronchoalveolar lavage . The brochoalveolar lavage send microscopy ( gram staining ) , culture fungal bacterial growth . Full dose therapeutic antifungal start early case development pneumonia , hemodynamic instability even 5 day antibiotic consider failure prophylaxis . Whenever feasible ( mandatory ) depend patient 's clinical condition , try obtain tissue sample histology FNAC/Biopsy suspect infected site .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>Patients age &lt; /= 15 year de novo acute leukemia ( AML , ALL ) undergo induction chemotherapy . No evidence fungal infection randomization No pneumonia presentation CXR . No systemic antifungal therapy within 7 day randomization . Febrile patient pneumonia , systemic fungal infection hemodynamically stable eligible study . Patients baseline pneumonia CXR . Laboratory evidence significant hepatic renal dysfunction ( define SGOT SGPT &gt; 5 time , Total bilirubin &gt; 2 time Serum creatinine &gt; 2 time upper limit normal )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Antifungal prophylaxis , acute leukemia induction ,</keyword>
</DOC>